Breast Cancer Research and Treatment

, Volume 71, Issue 1, pp 47–57

Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth

  • Chun-Hong Zhu
  • Frederick E. Domann
Article
  • 97 Downloads

Abstract

ErbB-3 (HER3) is a member of the epidermal growth factor receptor family. Increasing evidence suggests that elevated expression of ErbB-3 is important for malignancy. In this study, we found that elevated levels of ErbB-3 expression did not occur in the absence of AP-2γ in a panel of human mammary epithelial and fibroblasts cell lines. In contrast, there was no association between the expression of AP-2α or AP-2β and the level of ErbB-3, or between AP-2α and AP-2γ double positivity and ErbB-3 expression. In co-transfection experiments, exogenous expression of AP-2γ robustly activated ErbB-3 promoter activity. Moreover, expression of a dominant negative AP-2 protein, AP-2Delta; (deleted residues 31–117), not only repressed the ErbB-3 promoter activity but also suppressed endogenous ErbB-3 transcription in the ErbB-3 overexpressing cell line MRC-5VA. Overexpression of AP-2Δ resulted in a decreased proliferation rate and inhibition of colony formation. Taken together, these data strongly support a role for the AP-2 gene family, in particular, AP-2γ, in the control of ErbB-3 expression. Interference with the function of transcription factor AP-2 might provide a potential strategy for modulation of the malignant phenotype.

activator protein-2 breast cancer epidermal growth factor receptor heregulin neuregulin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    Prigent SA, Lemoine NR, Hughes CM, Plowman GD, Selden C, Gullick WJ: Expression of the c-c-erbB-3 protein in normal human adult and fetal tissues. Oncogene 7: 1273–1278, 1992Google Scholar
  2. 2.
    Stern DF, Kamps MP: EGF-stimulated tyrosine phosphorylation of p185neu: a potential model for receptor interactions. EMBO J 7(4): 995–1001, 1988Google Scholar
  3. 3.
    Plowman GD, Green JM, Culouscou JM, Carlton GW, Rothwell VM, Buckley S: Heregulin induces tyrosine phosphorylation of HER4/p180erbB4. Nature 366(6454): 473–475, 1993Google Scholar
  4. 4.
    Carraway KL, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti AJ, Vandlen RL, Cantley LC, Cerione RA: The erbB3 gene product is a receptor forheregulin.J Biol Chem 269(19): 14303–14306, 1994Google Scholar
  5. 5.
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785): 177–182, 1987Google Scholar
  6. 6.
    Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA: Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 86: 9193–9197, 1989Google Scholar
  7. 7.
    Gilbertson RJ, Clifford SC, MacMeekin W, Meekin W, Wright C, Perry RH, Kelly P, Pearson AD, Lunec J: Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res 58(17): 3932–3941, 1998Google Scholar
  8. 8.
    Darcy KM, Zangani D, Wohlhueter AL, Huang RY, Vaughan MM, Russell JA, Ip MM: Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells. J Histochem Cytochem 48(1): 63–80, 2000Google Scholar
  9. 9.
    Tuncer ZS, Vegh GL, Fulop V, Genest DR, Mok SC, Berkowitz RS: Expression of epidermal growth factor receptor-related family products in gestational trophoblastic diseases and normal placenta and its relationship with development of postmolar tumor. Gynecol Oncol 77(3): 389–393, 2000Google Scholar
  10. 10.
    Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL: Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91(17): 8132–8136, 1994Google Scholar
  11. 11.
    Borg A, Baldetorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H: ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81(2): 137–144, 1994Google Scholar
  12. 12.
    Sliwkowski MX, Schaefer G, Akita RW, Lofgren JA, Fitzpatrick VD, Nuijens A, Fendly BM, Cerione RA, Vandlen RL, Carraway KL: Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269(20): 14661–14665, 1994Google Scholar
  13. 13.
    Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMahon AP, Flavell RA, Williams T: Neural tube, seletal and body wall defects in mice lacking transcription factor AP-2. Nature 381: 238–241, 1996Google Scholar
  14. 14.
    Funayama T, Nakanishi T, Takahashi K, Taniguchi S, Takigawa M, Matsumura T: Overexpression of c-c-erbB-3 in various stages of human squamous cell carcinomas. Oncology 55(2): 161–167, 1998Google Scholar
  15. 15.
    Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC: Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66(6): 1116–1121, 1992Google Scholar
  16. 16.
    Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, Cagle PT: High c-c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol 10(2): 142–148, 1997Google Scholar
  17. 17.
    Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Spaventi S, Pavelic K, Spaventi R: J Cancer Res Clin Oncol 126: 205–211, 2000Google Scholar
  18. 18.
    Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ: Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 381: 235–238, 1996Google Scholar
  19. 19.
    Nottoli T, Hagopian-Donaldson S, Zhang J, Perkins A, Williams T: AP-2-null cells disrupt morphogenesis of the eye, face, and limbs in chimeric mice. Proc Natl Acad Sci USA 95: 13714–13719, 1998Google Scholar
  20. 20.
    Williamson JA, Bosher JM, Skinner A, Sheer D, Williams Tand Hurst HC: Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 35: 262–264, 1996Google Scholar
  21. 21.
    Gaynor RB, Muchardt C, Xia Y, Klisak I, Mohandas T, Sparkes RS, Lusis AJ: Localization of the gene for the DNAbinding protein AP-2 to human chromosome 6p22.3-pter. Genomics 10: 1100–1102, 1991Google Scholar
  22. 22.
    Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC: The developmental regulated transcription factor AP-2 is involved in ERBB2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92: 744–747, 1995Google Scholar
  23. 23.
    Kannan P, Buettner R, Chiao PJ, Yim SO, Sarkiss M, Tainsky MA: N-ras oncogene causes AP-2 transcriptional selfinterference,which leads to transformation. Genes Dev 8: 1258–1269, 1994Google Scholar
  24. 24.
    Bosher JM, Williams T, Hurst HC: The developmental regulated transcription factor AP-2 is involved in ERBB2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 92: 744–747, 1995.Google Scholar
  25. 25.
    Skinner A, Hurst HC Transcriptional regulation of the c-cerbB-3 gene in human breast carcinoma cell lines. Oncogene 8: 3393–3401, 1993Google Scholar
  26. 26.
    McPherson, LA„ Weigel RJ: AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs. Nucl Acids Res 27: 4040–4049, 1999Google Scholar
  27. 27.
    Zhu CH, Huang Y, Oberley LW, Domann FE: A family of AP-2 proteins down-regulate manganese superoxide dismutase expression. J Biol Chem 276(17): 14407–14413, 2001Google Scholar
  28. 28.
    Garcia MA, Campillos M, Marina A, Valdivieso F, Vazquez J: Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation. FEBS Lett 444(1): 27– 31, 1999Google Scholar
  29. 29.
    Nyormoi O, Wang Z, Doan D, Ruiz M, McConkey D, Bar-Eli M: Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteosome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells. Mol Cell Biol 21(15): 4856–4867, 2001Google Scholar
  30. 30.
    Williams T, Tjian R: Analysis of the DNA-binding and activation properties of the human transcription factor AP-2. Genes Dev 5: 670–682, 1991aGoogle Scholar
  31. 31.
    Moser M, Imhof A, Bauer R, Amselgruber W, Sinowartz F, Hofstadter F, Schule R, Buettner R: Cloning and characterization of a second AP-2 transcription factor: AP-2 beta. Development 121: 2779–2788, 1995Google Scholar
  32. 32.
    Alper O, De Santis ML, Stromberg K, Hacker NF, Cho-Chung YS, Salomon DS: Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, celladhesion and tumorigenicity in ovarian cancer cells. Int J Cancer 88(4): 566–574, 2000Google Scholar
  33. 33.
    Williams T, Tjian R: Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins. Science 251: 1067–1071, 1991bGoogle Scholar
  34. 34.
    Shen H, Wilkie T, Ashique AM, Narvey M, Zerucha T, Savino E, Williams T, Richman JM: Chicken transcription factor AP-2: cloning, expression and its role in outgrowth of facial prominences and limb buds. Dev Biol 188: 248–266, 1997Google Scholar
  35. 35.
    Monge I, Mitchell PJ: DAP-2, the Drosophila homolog of transcription factor AP-2. Mech Dev 76: 191–195, 1998Google Scholar
  36. 36.
    Wankhade S, Yu Y, Weinberg J, Tainsky MA, Kannan P: Characterization of the activation domains of AP-2 family transcription factors. J Biol Chem 275: 29701–29708, 2000Google Scholar
  37. 37.
    Moser M, Ruschoff J, Buettner R: Comparative analysis of AP-2 and AP-2 gene expression during murine embryogenesis. Dev Dyn 208: 115–124, 1997aGoogle Scholar
  38. 38.
    Moser M, Pscherer A, Roth C, Becker J, Mucher G, Zerres K, Dixkens C, Weis J, Guay-Woodford L, Buettner R, Fassler R: Enhanced apoptotic cell-death of renal epithelial cells in mice lacking transcription factor AP-2. Genes Dev 11: 1938–1948, 1997Google Scholar
  39. 39.
    Takahashi H, Oyama N, Itoh Y, Ishida-Yamamoto A, Kaneko F, Iizuka H: Transcriptional factor AP-2gamma increases human cystatin A gene transcription of keratinocytes.Biochem Biophys Res Commun 278(3): 719–723, 2000Google Scholar
  40. 40.
    Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, Glazer PM, Hurst HC, Haffty BG, Williams T: Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res 58: 5466–5472, 1998.Google Scholar
  41. 41.
    Huang Y, Domann FE: Transcription factor AP-2 mRNA and DNA binding activity are constitutively expressed in SV40-immortalized but not normal human lung fibroblasts. Arch Biochem Biophys 364: 241–246, 1999Google Scholar
  42. 42.
    Zhang L, Zhan S, Navid F, Li Q, Choi YH, Kim M, Seth P, Helman LJ:AP-2 may contribute to IGF-II overexpression in rhabdomyosarcoma. Oncogene 17(10): 1261–1270, 1998Google Scholar
  43. 43.
    Qin H, Sun Y, Benveniste EN: The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 274: 29130–29137, 1999Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • Chun-Hong Zhu
    • 1
  • Frederick E. Domann
    • 1
  1. 1.Free Radical & Radiation Biology Program, Department of Radiation Oncology, and Holden Comprehensive Cancer CenterThe University of IowaIowa City

Personalised recommendations